Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma

Jiayun JIANG; Hui ZHANG; Shiyu ZHANG; Jiejuan LAI; Yanjiao OU; Leida ZHANG

doi:10.16016/j.2097-0927.202405116

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma

Clinical Medicine | 更新时间：2026-01-09

- Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
- Journal of Army Medical University Vol. 46, Issue 22, Pages: 2529-2538(2024)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院肝胆外科
- 作者简介：
- 基金信息：
  
  the Through Train Project for Doctoral Scientific Research of Chongqing(CSTB2022BSXM-JCX0004);the Joint Medical Research Project of Chongqing Science and Technology Commission and Chongqing Health Commission(2022QNXM020);the General Project of Natural Science Foundation of Chongqing(cstc2021jcyj-msxmX1018)
- DOI：10.16016/j.2097-0927.202405116
  CLC： R181.23;R730.53;R735.7
- Received：30 May 2024，
  
  Revised：2024-06-28，
  
  Published：30 November 2024
- 稿件说明：
移动端阅览
Jiayun JIANG, Hui ZHANG, Shiyu ZHANG, et al. Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma[J]. Journal of Army Medical University, 2024, 46(22): 2529-2538.
DOI：

Jiayun JIANG, Hui ZHANG, Shiyu ZHANG, et al. Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma[J]. Journal of Army Medical University, 2024, 46(22): 2529-2538. DOI： 10.16016/j.2097-0927.202405116.

摘要

目的

分析经肝动脉化疗栓塞(transcatheter arterial chemoembolization

TACE)联合仑伐替尼及PD-1单抗的三联疗法治疗中晚期肝细胞癌(hepatocellular carcinoma，HCC)的疗效和安全性。

方法

本项目是一项回顾性队列研究。收集2021年1月至2023年6月陆军军医大学第一附属医院肝胆外科收治的105例行TACE联合仑伐替尼及PD-1单抗治疗的中晚期HCC患者的临床资料，收集患者TACE术前和术后随访的血生化指标及影像学特征，统计客观缓解率(objective response rate，ORR)、疾病控制率(disease control rate，DCR)、转化切除率、总生存期(overall survival

OS) 和无进展生存期(progression-free survival

PFS) 等指标评价三联疗法的临床疗效，记录治疗过程中出现的所有不良反应的频率及严重程度以评估三联疗法的安全性。

结果

105例接受三联治疗的中晚期HCC患者有33例死亡，72例仍存活。ORR为62.8%，DCR为72.3%，转化切除率为11.4%。中位总生存期(median overall survival

mOS)未达到。中位无进展生存期(median progression-free survival

mPFS)为(10.3±0.8)个月。所有等级不良反应发生率为97.1%，3~4级不良反应发生率为33.3%，无治疗相关的死亡病例发生。

结论

TACE联合仑伐替尼及PD-1单抗的三联疗法是一种安全、有效的综合治疗方案，为改善中晚期肝细胞癌的预后提供了新的治疗策略。

Abstract

Objective

To analyze the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and PD-1 antibody in the treatment of intermediate-advanced hepatocellular carcinoma (HCC).

Methods

A retrospective cohort trial was conducted on 105 patients with intermediate-advanced HCC (BCLC B or C stage) treated with TACE combined with lenvatinib and PD-1 antibody in our institute from January 2021 to June 2023. The blood biochemical indicators and imaging characteristics of the patients were collected before and after TACE. Objective response rate (ORR)

disease control rate (DCR)

conversion resection rate

overall survival (OS) and progression-free survival (PFS) were analyzed to evaluate the clinical efficacy of the triple therapy

and the frequency and severity of all adverse reactions during treatment were recorded to evaluate the safety of the therapy.

Results

Among the 105 patients with intermediate-advanced HCC who received triple therapy

33 died and 72 survived. The ORR was 62.8% and the DCR was 72.3%. The conversion resection rate was 11.4%. The median OS (mOS) was not reached. The median PFS (mPFS) was (10.3±0.8) months. The incidence of adverse reactions of all grades was 97.1%

and the incidence of those of grade 3~4 was 33.3%. No treatment-related death occurred.

Conclusion

The triple therapy of TACE combined with lenvatinib and PD-1 antibody is a safe and effective comprehensive treatment regimen

which provides a new treatment strategy for improving the prognosis of intermediate-advanced HCC.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Cli n, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(4): 367-388. DOI: 10.3760/cma.j.cn501113-20220413-00193.

Medical Administration Bureou of National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)[J]. Chin J Hepatol, 2022, 30(4): 367-388. DOI: 10.3760/cma.j.cn501113-20220413-00193.

BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853. DOI: 10.1053/j.gastro.2015.12.041.

中国抗癌协会肝癌专业委员会转化治疗协作组, 樊嘉, 秦叔逵, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 7(6): 618-632.

Alliance of Liver Cancer Translational Therapy of Liver Cancer Committee of the Chinese Anti-Cancer Association, FAN J, QIN S K, et al . Chinese expert consensus on conversion therapy in hepatocellular carcinoma(2021 edition)[J ] . Chin J Pract Surg, 2021, 7(6): 618-632.

RAO Q, LI M, XU W, et al . Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis[J ] . Hepatol Int, 2020, 14( 5): 765-775. DOI: 10.1007/s12072-020-10064-8.

FINN R S, IKEDA M, ZHU A X, et al . Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J ] . J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.

中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 中华肝胆外科杂志, 2021, 27(4): 241-251. DOI: 10.3760/cma.j.cn113884-20210415-00138.

Hepatobiliary and Pancreatic Disease Prevention and Control Committee of Chinese Preventive Medical Association, Liver Cancer Committee of Chinese Anti-Cancer Association, Hepatology Group of Surgery Branch of Beijing Medical Association, et al . Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition)[J ] . Chin J Hepatobiliary Surg, 2021, 27(4): 241-251. DOI: 10.3760/cma.j.cn113884-20210415-00138.

ZHU X D, HUANG C, SHEN Y H, et al . Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10(4): 320-329. DOI: 10.1159/000514313.

LLOVET J M, LENCIONI R. mRECIST for HCC: Performance and novel refinements[J]. J Hepatol, 2020, 72(2): 288-306. DOI: 10.1016/j.jhep.2019.09.026.

LUO J, GUO R P, LAI E C, et al . Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J ] . Ann Surg Oncol, 2011, 18(2): 413-420. DOI: 10.1245/s10434-010-1321-8.

ZHU K S, CHEN J W, LAI L S, et al . Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib: a retrospective controlled study[J ] . Radiology, 2014, 272(1): 284-293. DOI: 10.1148/radiol.14131946.

SILVA J P, BERGER N G, TSAI S, et al . Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis[J ] . HPB, 2017, 19(8): 659-666. DOI: 10.1016/j.hpb.2017.04.016.

FAN J, TANG Z Y, YU Y Q, et al . Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J ] . Dig Surg, 1998, 15(6): 674-678. DOI: 10.1159/000018676.

SERGIO A, CRISTOFORI C, CARDIN R, et al . Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness[J ] . Am J Gastroenterol, 2008, 103(4): 914-921. DOI: 10.1111/j.1572-0241.2007.01712.x.

VIRMANI S, RHEE T K, RYU R K, et al . Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors[J ] . J Vasc Interv Radiol, 2008, 19(10): 1483-1489. DOI: 10.1016/j.jvir.2008.06.017.

PINATO D J, MURRAY S M, FORNER A, et al . Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy[J ] . J Immunother Cancer, 2021, 9(9): e003311. DOI: 10.1136/jitc-2021-003311.

WANG B, XU H, GAO Z Q, et al . Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J ] . Acta Radiol, 2008, 49(5): 523-529. DOI: 10.1080/02841850801958890.

中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31(11): 1039-1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.

Clinical Guidelines Committee of Interventional Physician Branch of Chinese Medical Doctor Association. Expert consensus on the TACE failure/refractoriness and its subsequent therapies in treating patients with hepatocellular carcinoma[J]. J Interv Radiol, 2022, 31(11): 1039-1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.

魏庭丰, 何仕诚, 朱海东, 等. 原发性肝癌肝动脉化疗栓塞治疗间隔长短对近期肝功能影响的比较[J]. 介入放射学杂志, 2020, 29(11): 1126-1130. DOI: 10.3969/j.issn.1008-794X.2020.11.014.

WEI T F, HE S C, ZHU H D, et al . The impact of different intervals between two TACE procedures on the short-term liver functions in patients with hepatocellular carcinoma[J ] . J Interv Radiol, 2020, 29(11): 1126-1130. DOI: 10.3969/j.issn.1008-794X.2020.11.014.

FINN R S, QIN S K, IKEDA M, et al . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J ] . N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.

REN Z G, XU J M, BAI Y X, et al . Sintilimab plus a bevacizumab biosimilar (IBI 3 05) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J ] . Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7..

XU J M, SHEN J, GU S Z, et al . Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J ] . Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571.

ZHU X D, HUANG C, SHEN Y H, et al . Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J ] . Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313.

张雯雯, 胡丙洋, 韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 6(12): 947-948.

ZHANG W W, HU B Y, HAN J, et al . Preliminary report on the study of conversion therapy of advanced hepatocellular carcinoma combined PD-1 inhibitors with multi-target tyrosine kinase inhibitors[J ] . Chin J Hepatobiliary Surg, 2020, 6(12): 947-948.

ZHANG W W, TONG S, HU B Y, et al . Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase Ⅱ trial[J ] . J Immunother Cancer, 2023, 11(9): e007366. DOI: 10.1136/jitc-2023-007366.

NOMAN M Z, DESANTIS G, JANJI B, et al . PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxi a enhanced MDSC-mediated T cell activation[J ] . J Exp Med, 2014, 211(5): 781-790. DOI: 10.1084/jem.20131916.

PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Emerging advances in clinical diagnosis and treatment of hepatocellular carcinoma: evolution of comprehensive treatment strategies

SLC38A1 drives malignant progression of hepatocellular carcinoma by activating PI3K/AKT signaling via enhanced glutamine uptake

PD-L1 promotes hepatocellular carcinoma progression by inhibiting PTP1B and activating FAK

Nuclear EGFR cooperates with YY1 to drive CEMIP expression and enhance hepatocellular carcinoma invasion

GPX7 regulates proliferation and senescence of hepatocellular carcinoma cells through the PI3K-AKT pathway

Related Author

LI Jianwei

WANG Xingru

YANG Yuanyuan

ZHANG Ping

HU Peng

LIU Maonian

OU Yanjiao

LIU Yang

Related Institution

No.953，Xigaze， Tibet Autonomous Region

Institute of Hepatobiliary Surgery of PLA，First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Hepatobiliary， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Digestive Disease Center， Chongqing Hygeia Hospital

Grade Majoring in Clinical Medicine， School of Medicine， Anhui University of Science and Technology

⁰